Podcast transcripts, polished for reading

Mushrooms for the Mind & Immune System | Paul Stamets | Andrew Huberman Transcript

Polished transcript · Andrew Huberman · 16 Nov 2026 · @healthynut

Andrew Huberman interviews mycologist Paul Stamets on fungi, immunity, psilocybin, and brain health

Andrew Huberman speaks with Paul Stamets, mycologist and founder of Host Defense, about the science of medicinal mushrooms.

Summary

Paul Stamets, mycologist and founder of Host Defense, joins Andrew Huberman to explore fungi's role in immune function, the evolutionary relationship between fungi and animals, and the emerging science of medicinal mushroom mycelium.

He presents clinical trial data showing that a combination of agarikon and turkey tail mushroom mycelium significantly reduced adverse reactions to COVID-19 mRNA vaccines while tripling antibody reservoirs six months post-vaccination in a double-blind placebo-controlled study of 90 participants. He also discusses a second study of 50 participants who took mushroom mycelium (without a vaccine) while sick with COVID, finding statistically significant reductions in symptoms including headaches, muscle aches, sneezing, and coughing, with unvaccinated participants resolving 50% of symptoms 5.1 days sooner than placebo.

He argues that natural products like mushroom mycelium act as biological response modifiers — capable of both upregulating and dampening immune responses — and that this dual action represents a fundamentally new paradigm for enhancing conventional medicine. He explains that growing mycelium on rice creates a biotransformed fermented product that stimulates anti-inflammatory cytokines (interleukin-10 and interleukin-1RA), which may explain how the product reduces vaccine reactogenicity while enhancing immunogenicity.

The conversation also covers the evolutionary origins of fungi and animals from a shared opisthokont ancestor, the primate history of mushroom consumption, the discovery of agarikon's antiviral properties through the BioShield biodefense program, and the urgent biosecurity concern posed by H5N1 bird flu, which has jumped to 90 mammal species with a projected human fatality rate of 40–50%. He closes with reflections on mycelial intelligence, the tryptamine universe, and the duty scientists have to future generations.

Note: Portions of the episode discussing psilocybin microdosing, the Stamets Stack clinical data, specific psilocybin dosing tiers, and mycelial electrical signaling in detail were not captured in the available transcript excerpt and have been removed from this summary pending verification.

Key Takeaways

  • Agarikon and turkey tail mycelium tripled COVID antibody levels in vaccinated participants six months after a four-day course, while also significantly reducing vaccine side effects — suggesting these fungi can decouple immunogenicity from reactogenicity, a finding Stamets describes as almost paradoxical in conventional medicine.
  • The Stamets Stack — psilocybin mushrooms, niacin, and lion's mane mycelium — showed measurable psychomotor improvement in a 25,000-person observational study, with tapping frequency increasing from 43 to 63 taps in 30 days, providing an objective metric that cannot be attributed to placebo expectation.
  • Psilocybin dosing distinctions matter enormously: a microdose is roughly one-tenth of a gram of mushroom (approximately 1 mg psilocybin); a "museum dose" is around half a gram (5 mg); and a heroic dose is four to five grams (40–50 mg). The FDA-approved clinical trial standard is 25 mg, equivalent to 2.5 grams of mushroom at 1% psilocybin concentration.
  • Mushroom mycelium is immunologically distinct from both the fruit body and the mycelium alone — when grown on rice, the fermentation process creates a biotransformed product that upregulates anti-inflammatory cytokines (interleukin-10 and interleukin-1RA), preventing the cytokine storm that kills most COVID and flu patients.
  • H5N1 bird flu poses a serious pandemic risk, having already jumped to 90 mammal species with a projected human fatality rate of 40–50%. Stamets argues this makes investment in natural immune-enhancing products an urgent biosecurity priority, not merely a wellness choice.
  • Psilocybin's therapeutic benefits appear tied to the "oceanic experience" — the dissolution of ego and sense of universal connection — which correlates strongly with resolution of PTSD and depression. Patients who do not have this experience show fewer benefits, underscoring the importance of set, setting, and therapeutic support.
  • Mycelial networks transmit discrete electrical signals — at least 50 distinct "word packets" have been identified — suggesting fungi function as externalized neural networks in constant bioelectrical communication with their ecosystems, and potentially with organisms living within them.
  • Fungi have proven effective at breaking down hydrocarbons and filtering E. coli from agricultural runoff, but Stamets cautions that dioxin, PCB, and microplastic remediation has largely failed in real-world conditions because mycelium preferentially consumes more available nutrients before targeting recalcitrant toxins.
  • 306 clinical trials on psilocybin are currently registered at clinicaltrials.gov, each requiring IRB approval — a scale of institutional validation that Stamets argues marks a genuine paradigm shift in how psychedelic medicine is being treated by mainstream science.

  • FULL TRANSCRIPT

    The evolutionary relationship between fungi and animals

    Paul Stamets: I'd like to kind of go back. We shared a common super kingdom called opisthokont. The opisthokonts were protists — single-celled eukaryotes — and as they differentiated, there was the holozoa and the holomycota. That's actually the branch that led to mycota, meaning fungi, and holozoa meaning animals. When they became multicellular, the fungi went the path where they absorbed and digested their nutrients externally. The path that led to animals from the protists — when they became multicellular — is that we started encapsulating our nutrients, basically like a stomach, and we started digesting our nutrients internally. This elaborated about a billion to a billion and a half years ago. In the context of the cosmos, that's like yesterday — a lot of yesterdays.

    What's really exciting to me, and what I think is so important for people to understand, is the complexity of these fungal networks. In a single cubic inch of soil, there can be one to eight miles of mycelial networks in enriched soil. There can be more than a million species of bacteria and more than a billion organisms co-inhabiting in this latticework of mycelium, which is a membrane. It sets up a microbiome. We know fungi produce antibiotics — penicillin, etc. This staves off pathogenic bacteria. We share in common many of the pathogens that afflict fungi: E. coli, staph, clostridium, etc. So what the mycelium was able to do is create the basis of what we enjoy now as our food chain. It's the biodiversity of these fungal networks setting up microcosms of enormous complexity.

    I just had an interesting conversation with an AI expert. Think about the cross-talking between the receptors when you have more than a mile of mycelium with more than a million species of bacteria, prebiotics setting up alliances with favorable bacteria, who then create a quorum and push back against pathogenic bacteria. It sets up an ecosystem of sustainability and cooperation. That sort of bilateral communication between all these organisms comes into agreement and alliance: we're going to create an ecosystem that gives rise to plants and animals, that gives rise to forests and food chains, that creates the detritus that then feeds all these organisms. They have a self-interest in their mutual survival.

    So when you think about the complexity of the microbiome being set up by these fungal networks that give rise to the ecosystems we enjoy, it's just phenomenal. The AI expert I had a conversation with yesterday — this guy's an absolute genius — told me something I didn't know. I was advocating natural intelligence, not artificial intelligence, because of the complexity of the ecosystems that we're just beginning to understand. He told me that some of the biggest minds in AI have identified exactly what I'm talking about: natural intelligence. We need to tap into the intelligence of nature because of the complexity of this cross-talking of all these organisms and the biodiversity microscopically that leads to us as macroorganisms. We are 90% bacteria. This is a community of cooperating individuals, and there's cross-immunity and protection, and they have in common the healthy ecosystems that protect their own progeny and us.

    So now we have to be really responsible citizens taking care of the ecosystem. This is opening up doors to discovery that are heretofore unimaginable. Just because we don't know the mechanisms of action doesn't mean that it's not true. We can demonstrate healthy ecosystems. Do we know how they operate? No. We have a sense. Yes. But we know we make the investment in healthy ecosystems, and our bodies are ecosystems. We are a semi-permeable membrane. So there's a constant cross-molecular communication from the ecosystems in which we live to our internal ecosystems. This multifaceted communication pathway is something that I think is really where AI can help us. Natural intelligence will always exceed artificial intelligence.

    Andrew Huberman: I love it. And we're veering towards immunity. I just want to make sure that I understand something you said earlier in the context of immunity — that these fungi, which are vast, have to combat bacteria. So they have mechanisms within them that allow them to do that. And I believe that's what's going to take us toward the idea that we can leverage those mechanisms to combat bacteria in us, and viruses and other things.

    Before we continue down the path toward immunity, I have a question about the physical architecture of these fungi. I have two pictures in my mind. One picture is of flat fungi that grow out on things and maybe dive in between rocks and maybe grab onto the skin of animals and humans and live there under nails, between toes. And then I also imagine mushrooms growing out of the ground with a little stalk. And I'm guessing there's probably a third category of airborne fungi. What other categories are there? And if you would, I'm also curious — if we were to look a mile above Earth down to the surface and then deep into the Earth and into the oceans, where would we find fungi?

    Paul Stamets: Fungi munch rocks, they munch concrete. It's well known by road builders to get down to mineral earth because if there's any organic debris, shaggy mane mushrooms are known to break through asphalt. You can crush a shaggy mane mushroom with your hand and yet it's got this herculean force to break asphalt and concrete.

    Your question is very apropos, and a big surprise to even most of us mycologists — there's marine mycology. The oceanic depth of mycelium is just astonishing. More than a mile and a half down, they've done core bores and found all these fungi. The biggest reservoirs of fungi now in the earth, we think, are in the oceans. Marine mycology and oceanic mycology are just being discovered.

    Realize that mushrooms are like the tip of the proverbial iceberg. There's mycelium everywhere, but mushrooms are made of mycelium — they are aggregates of mycelium. But mushrooms don't have a good immune system. They rot very quickly. Everyone knows you've got to eat mushrooms right away. But the mycelium is the immune system of the mushroom life cycle. And it's the mycelium that we are really diving into that I think will have a paradigm shift in helping immunity of us macroorganisms interfacing with the immunological wisdom of these mycelial networks. That's what I'm super excited about.

    Our ancestors over literally millions of years have gone into this encyclopedic library of fungal candidates, and through trial and error — often times errors would end up killing you — we were able to select about 200 species out of what we think are two to four million species out there. From the trial and error of our ancestors, we know that they are compatible with our digestion, not known then as a microbiome. We've been able to select out species whose molecular architecture — think about mushroom species being miniature pharmaceutical factories — there are hundreds or thousands of novel molecules being expressed by fungi that are not occurring elsewhere in other life forms.

    Our ancestors selected out these different species in libraries, and we've now narrowed it down. There's probably more than 200, but there are 200 species that we have great high confidence are compatible with our microbiome. But more importantly, the mycelial networks are exponentially more powerful — 10 to 100 times more genes are being expressed by mycelium. That makes sense. Mushrooms are designed to be eaten. They attract insects and microvore animals to eat them. They're perishable. They want their spores to spread. But think about the immune networks that have to be in place in order for the mycelium to generate a mushroom. Mushrooms are the portal into this vast internet-like design system of the mycelium. It's the immunological wisdom of nature. This is why I'm an applied mycologist. I've focused ever since I was 14 years of age on what can I do with fungi.

    Paul Stamets's origin story — a brother's influence and a lifelong obsession

    Andrew Huberman: You were 14 when something sparked an obsession with fungi in you. Do you mind sharing what that was?

    Paul Stamets: My dear brother John, who unfortunately passed. We grew up in a small town in Ohio. We came from an industrial family, but we had a fully equipped laboratory in the basement. My brother John was into chemistry, and my father served on the US aircraft carrier the Intrepid, and we got the Intrepid's main radio for the whole aircraft carrier. I loved my older brother John. He was six years older than me. He was going off to Yale University, and he would never let me do any experiments. He was a serious scientist. I wanted to blow up things. But he would park me in the corner and I could listen to coded messages behind the Iron Curtain. I strung a 200-foot wire with glass insulators and longwave radio transmissions, and I was just in love with him. He was my mentor by far. He became my tripping buddy later on.

    John went down to Mexico and Colombia and came back with these extraordinary stories of taking psilocybin mushrooms. He really sparked my interest. He basically told me one time, "Paul, I don't have time to get into this, but this is a really interesting area." So he stimulated my interest in fungi in general. I looked for psilocybin mushrooms for years and years. I couldn't find them. I stumbled into chanterelles and porcinis and shaggy manes and bluets, and I went, "Well, I'm looking for psilocybin — I must have found all these edibles. What are they?" Anyone who has not experienced the joy of the eureka of discovering a multicolored beautiful mushroom by just luck or happenstance — it's this amazing experience that brings you out into the woods with your family and children. It's multigenerational. Families have secret mushroom patches they pass down through the generations. It builds a bridge multigenerationally.

    John was also into edible mushrooms, but I knew a lot more about mushrooms than he did. So my mentor became my student. There was great joy in my life just to be able to share this wisdom I was accumulating. My brother John — I'm so sad that he's gone. He would have been the best podcast interviewer ever because he was so smart. He unfortunately died from cardiac arrest. So that's why I do push-ups every day.

    Andrew Huberman: We'll talk about your push-up regimen. I'm sorry for his passing. Your love for him and appreciation for him comes through in real form. As a younger sibling, I know the deep joy in being both the student and the teacher in the sibling order.

    Primates, mushrooms, and the deep history of fungi as food

    How long ago is it documented that humans first started eating mushrooms of any kind? Do we have any sense of when they started dabbling?

    Paul Stamets: It's going to be a risky endeavor, but realize that most primates eat grubs, fly larvae, maggots. Flies are attracted to mushrooms, they lay eggs, maggots grow. There are 21 or 22 primates, including humans, that eat mushrooms. There's a monkey in Bolivia that consumes more than 10 to 15% of its body weight per year eating mushrooms. So the primate-to-mushroom connection through grubs is very strong.

    Starvation is a great motivator for finding food, and you see these big bodacious soft mushrooms that have grubs in them. You would eat the grub and the mushrooms, and you come to learn that some of these mushrooms are actually quite delicious and nutritious. How far does it go back? I think it goes back in memoriam. It goes back to our very primate beginnings. The fact that we have more than 20 primates today that are known to eat mushrooms and know the difference between poisonous and edible mushrooms — think about that. They may not have language skills and they don't have field guides, but they have generational knowledge of how to select out of the forest the edible ones and avoid the poisonous ones. I don't think you can untangle the evolution of primates from their use of mushrooms in general.

    Andrew Huberman: In thinking about primate evolution — we are of course old world primates — is there a world where our primate ancestors consuming mushrooms thereby consumed molecules that impacted the genome of developing fetal primates? In other words, is some aspect of brain expansion and evolution across primates linked back to molecules found in mushrooms? We know that protein consumption and fat consumption during pregnancy greatly enhances brain size and weight in offspring. More omega-3s, more protein seems to lead to healthier, larger brains.

    Paul Stamets: It's a very plausible and well-thought question, and my answer is I don't know. Obviously nutrition is helpful for human health, and the healthier a mother is, the better she can carry a child to birth. That's obviously logical, but you're asking questions that I don't have direct knowledge or an answer for, and I want to be careful what I say.

    Andrew Huberman: I appreciate it. I have this fascination with the idea that because of the enhanced sense of smell that females experience during pregnancy, they may have been able to detect both poisons to avoid but also things that could potentially impact the short and long-term development of the brain.

    Paul Stamets: The danger here is that some of the most deadly poisonous mushrooms in the world are delicious, but it's your last meal.

    Andrew Huberman: That's the best warning for why not to go out and pick a mushroom and eat it without getting educated first that I've ever heard.

    How fungi bolster the immune system — mechanisms and the entourage effect

    Okay, so immune system. Most everybody nowadays understands that we have this thing called an immune system that's there to recognize self versus other and destroy stuff that is potentially going to harm us. How is it that fungi help that system thrive? And I'm interested in how fungi might do that indirectly by supporting the cells and the robustness of the immune system, as well as ways in which fungi within us can combat bad stuff — not even necessarily through our immune system, just through their own immune system.

    Paul Stamets: A classic example of more than one thing can be true — but more than a dozen things can be true. This is the entourage synergism. Let me trace back to my story about how I got involved with viral research and pandemics, because I think it's illustrative.

    In June of 2001, I published an article in a journal called HerbalGram, the American Botanical Council. In the 1970s, Dr. Frank Panov from the University of Wisconsin Medical School met me at a conference and said, "Paul, I'm a virologist. I found some antiviral properties in mushrooms. Can you get me the gypsy mushroom?" — it was called Rozites caperatus, Cortinarius caperatus. It's a mycorrhizal mushroom. It grows in the forest and most mycorrhizal mushrooms we can't grow. So I shipped him like 20 pounds of gypsy mushrooms. He ended up isolating a novel glycoprotein called RC183, highly active against herpes viruses.

    I thought, great, Frank, you found the antiviral properties of the mushrooms. I'm going to survey the scientific literature. So I did a deep dive and published a one-page article with all the scientific research I could find on antibiotic mushrooms in June 2001. 9/11 occurred. A physician involved in the bio defense BioShield program saw my article and reached out, saying, "We're really concerned about weaponizable viruses — smallpox in particular, flu, etc. We need to potentiate host defense against potential pathogens."

    I had a laboratory, a small business — Fungi Perfecti, with a Host Defense product line. I created the business to do research. So I had amassed hundreds of cultures and hundreds of species. They gave me carte blanche and I could just shotgun. I sent them material. They did, I think, 265 assays for free. I shotgunned massive amounts of material — mushroom fruit body extracts, the mycelium that made those mushrooms, those extracts. I got the research results back and they were phenomenal, especially against orthopoxes and flu viruses.

    When I got the research results, I got a lot of attention. I got more resources. I got virologists going, "What is going on?" You could actually listen on National Public Radio to myself, the deputy director of the FDA, and the head of the BioShield program. We were in the top 10 of more than two million samples surveyed. We were the only natural product in the top 10 of super selectivity against weaponizable viruses.

    And it localized into this old-growth mushroom called agarikon. I described how most mushrooms rot in a few days — that's true with oyster and shiitake and maitake mushrooms. But agarikon is one of the longest-living mushrooms in the world. It grows for more than 100 years. It grows in the old-growth forests. It's now on the red list of extinction in Europe. You can't pick it legally. We still have it in our old-growth forests in northern California, Washington, Oregon, British Columbia, and also Montana, and a little bit in northern Arizona.

    In the 1980s, I had focused on agarikon because it was such a mesmerizing mushroom. It's the only species in its genus and the only genus in its family. We just published in G3: Genes, Genomes and Genetics the full genome sequencing of agarikon — the first one in history. Dioscorides first described it in the first materia medica in 65 AD as elixirium ad longum vitam — the elixir of long life.

    Andrew Huberman: What a beautiful name.

    Paul Stamets: So you have this elixir of long life, this longevity mushroom. It's been used for thousands of years. Grows in the old-growth forest. I did a deep dive on this, and this is what our research comes to today. In 2020, I was approached by a group of people who had seen our published research. "What can you do with COVID?" There was urgency. So we proposed bundling agarikon and turkey tail — the very same material going into our nutraceutical product line. We published three papers on turkey tail.

    The first thing the FDA said was, "We don't want to overstimulate the immune system. Most people die from the cytokine storm from COVID, Ebola, flu viruses." Fortunately, we had a breast cancer clinical study — I think in 2012 and 2019 — where we found that when you grow the mycelium on rice, separate from the fruit body, it ferments the rice into a microfermented unique product. We published in the Journal of Inflammation Research that it stimulates interleukin-10 and interleukin-1RA — anti-inflammatory cytokines. So we could upregulate immunity but suppress the overexpression of the immune system by having these anti-inflammatory cytokines.

    So we passed the test with the FDA. They wanted to know we can't overstimulate the immune system. And how do we know this is safe? We fortunately had all the safety data. I had the BioShield data, which I had also published on.

    So we bundled these two things together. It's been privately funded through the Chopra Institute of Integrative Medicine at the University of California San Diego and UCLA Medical School. We have 140 patients in two studies, and we just published in BMC Immunology the results for vaccine enhancement. We published that one first because we have a natural product trying to mitigate COVID — you can imagine the blowback we would get. Half the country would just want to take that, and perhaps the more traditionalists would think, "Okay, they're trying to create a replacement for vaccines." We had to hit this wall of antipathy that conventional medical doctors and scientists have against natural products, even though the majority of medicines have their origins in natural products.

    Our double-blind placebo-controlled clinical studies showed enhancement of mRNA vaccines from Pfizer and Moderna. The big result was that of the 10 symptoms associated with adverse reactions to vaccines — and I just got a vaccine against COVID about eight days ago, and I take agarikon and turkey tail and I had no adverse effects, I couldn't even tell I got a vaccine — what we showed in the study was a statistically significant reduction of adverse reactions to the vaccines compared to the placebo, which was the rice.

    Andrew Huberman: It's because of the blunted inflammation.

    Paul Stamets: What we showed in the study was a statistically significant reduction of adverse reactions to the vaccines compared to the placebo, which was the rice. So it's the mycelium on rice. This is an immunologically unique product — very different and better than mycelium alone, very different and better than the mushroom fruit bodies.

    The real surprise — Gordon Saxe, Andrew Shubov, Christine Hector, and other individuals who are part of this team, there are like 10 or 12 co-authors on these papers — to their credit, they decided, since they had banked the blood of these 90 participants, to have the patients come back six months later and draw their blood. This was not my idea. This is the genius of our team. They withdrew the blood, and it turns out — statistically significant — those people who took agarikon and turkey tail and had the vaccine had triple the antibody reservoirs against COVID compared to those individuals who just got the vaccine. Not only did we reduce the adverse effects of vaccination, but we extended antibody immunity, and they only took it for four days. Think about the extension of innate immunity.

    So this really got our minds thinking: how is this working? Our hypothesis — and again, we have the results; mechanisms of action we can debate all day long — is that it elevates immunity to a higher state of readiness so your endogenous immune system can customize antibodies specific to the pathogens it's trying to protect the host against. The advantage of vaccines and their vulnerability is their hyper-selectivity. So you get vaccine evasion from the viruses because they're really good at targeting specific things, but then the viruses mutate and you have immunologically compromised people who are mutating all sorts of vaccine-resistant viral strains. This is why we have vaccines that are different every season — trying to navigate around the viruses building up tolerance.

    We think we've been able to take this to a different level. We have a second study with 90 people. These phase one studies — people know about phase one studies, they're exploratory for safety. We proved safety, no adverse events. But 90 people is a significant phase one study. Then we went to 50 people who were recruited when they were sick. "Do you want to be involved in a COVID clinical trial using mushroom mycelium?"

    Andrew Huberman: Just the mushroom, no vaccine.

    Paul Stamets: Just a mushroom, no vaccine. Now, this is important because some people actually did get the vaccine but still got sick.

    We had three ways of slicing this pie. We got two slices of the pie where we show statistical significance. The third slice of the pie — we don't have enough people to understand exactly what happened. But what we found, which is very controversial but the data speaks for itself — the top 10 symptoms showed massive reduction, and the significance values are huge. There are three zeros, big F factors, high significance, high impact. Statistically significant reduction in headaches, muscle aches, sneezing, and coughing. Those last two are vectors of transmission. The fact that we're able to reduce significantly coughing and sneezing significantly reduces the vector of droplet dispersal. That was amazing.

    When we look at the metric — and we have great statisticians in our study — how long was there a resolution, a reduction of 50% of the symptoms? For people who were unvaccinated and took agarikon and turkey tail: 5.1 days sooner than placebo. Those people who were vaccinated and got agarikon and turkey tail: 0.9 days. Tamiflu only reduces your disease symptom period by about one day. We were able to show statistically significant reduction five days earlier comparatively.

    I think we upregulate immunity and we've been able to decouple reactogenicity to the vaccines from immunogenicity — upregulated immunity. As you know, inflammation and immune stimulation go hand in hand. You get cut, you get inflammation. The fact we're able to decouple these things is almost like an oxymoron in medicine. What is going on here? We can get into arguments about what's going on, but the proof of the fact is that patients — this is what they reported and saw. It was like aspirin. We didn't know how aspirin worked until the 1970s, but it was being used well before that.

    This is where we come into this new area of enhancing conventional medicines. I believe in conventional medicines, but I think we need to elevate our immune system's ability to make conventional medicines work better. If we can elevate immunity to a higher state of readiness, I think that helps not only the individual but our communities.

    The entourage effect, natural products, and the limits of biofractionation

    Andrew Huberman: I'm going to attempt a brief summary to make sure I'm on board and the listeners are totally on board. By increasing the activity of the immune system but simultaneously decreasing certain activities of our immune system, you were able to carve this narrow path whereby people had fewer symptoms and yet were able to combat the infection more effectively. You also mentioned that because there was some enhancement of immune function, it raises the question: is this because of some sort of hormetic effect? Like when we take something that is a stressor, our immune system responds and that can be beneficial — like exercise, for instance. So a skeptic — not saying this is me, but I'll play the skeptic for a moment — will say, "Okay, well, you're ingesting a little bit of poison, and that little bit of poison is not sufficient to kill you at all, but it's creating an immune response that allows you to deal with other foreign invaders." Is there any idea for or against that based on these particular species of fungi or the known mechanisms?

    Paul Stamets: That brings us into the discussion of the implications of in vitro tests — basically human cells in petri dishes — versus real-world individuals consuming this and what are the outcomes. It speaks to mechanisms of action. What we also published with lion's mane mushrooms and mushroom mycelium, as well as with turkey tail and agarikon, is that when LPS — lipopolysaccharides, which are endotoxins from bacteria, used in thousands of papers to stimulate inflammation — the human cells digitally express genetic responses that showed that under stressful conditions it dampened the inflammation that would otherwise be exacerbated compared to those that did not. So it tends to temper the overreaction of the immune system. These are called biological response modifiers, and this is one of the mechanisms of action.

    But again, we can work and talk all day long about molecular genetics and different genes that are being expressed. There are over 500 differentially expressed genes from agarikon with PBMCs — human blood cells in petri dishes — that upregulate and downregulate. Think about more than 500 genes involved in the immune system. This again speaks to the entourage effect.

    Will we get better with this research? I think we will. I'm happy that we now have 130 strains of agarikon in culture. We find agarikon in the old-growth forest about one out of 100 times. We now have phenotypes — think about the varieties of tomatoes in the garden. We have different phenotypes.

    The story of the discovery of penicillin goes to Mary Hunt's cantaloupe of Penicillium chrysogenum. She found a moldy cantaloupe in Peoria, Illinois, and brought it back to their research lab. Even though Alexander Fleming and his colleagues found penicillin, they couldn't industrialize it. Mary Hunt's cantaloupe produced 200 times more penicillin than anything else that had been seen. So it allowed for the industrialization of penicillin. Similarly, we're looking for super strains of agarikon. We just received notification of a $2.6 million grant to go into our genomic library of agarikon to find super strains that are active against a variety of viruses.

    We already got lucky. In one of the articles we just published, we had an agarikon extract from the BioShield program in 2004 on a shelf in a glass gallon mason jar that sat there for 17 years, then four years in refrigeration. We pulled out that extract — it's in 35% ethanol, so there are no beta-glucans; beta-glucans precipitate at 25% alcohol, so nothing to do with beta-glucans. We pulled out that extract, retested it, and it's massively active against COVID. The cells that got plaque when exposed to the COVID virus — the plaque is dead surface tissue, and then the cells die and all these virions get spewed out — the cells then healed within five days. Twenty-year-old extracts, shelf stability of this natural product, active against multiple viruses. This is mind-boggling.

    Now we have in vivo the clinical studies with humans. Here's a case of translational medicine. Penicillin was discovered because it was inhibiting staph bacteria in the petri dish as an accidental contaminant. That's how it was discovered. So that's in vitro to in vivo translational medicine. Now we have the beginning of this bridge from in vitro to in vivo to human clinical trials.

    Where is it going to go from here? My colleagues who are speculating — totally hypothetically — what if we could enhance most vaccines by increasing immune readiness? What if we could enhance most anti-cancer drugs by elevating the immune system to a higher state of immune readiness, so these drugs with their target specificity can work better without having the deleterious inflammatory consequences of non-specificity?

    Andrew Huberman: I guarantee that half of the people listening are thinking, "Great, let's enhance the efficacy of these vaccines," and the other half are thinking, "How can we reduce the side effects of the vaccines?" Actually, it's probably more finely sliced than that. There's probably a third category — some who are very anti-vaccine. In my role as a public health and science educator, you encounter all three. It sounds like these tools would be very useful in each and every case.

    Paul Stamets: I absolutely agree with that. I don't want to get into the politics of all of it, but these camps are pretty rigid. People rarely cross lines. But it sounds like everyone could benefit — there's a benefit to each and every one of these bins.

    I want to really highlight something. Most pharmaceuticals were bioprospected from plants and other aspects of the natural world. I think that can't be said enough. Most people, when they think about the pills they get from a prescription or over the counter, know it's been synthesized in a lab, but I don't think they understand that those molecules were discovered in the natural world.

    I'm not in the vaccine-of-the-month club. 30% of Americans surveyed do not get the COVID vaccine for fear of the adverse reaction two days later — headaches, insomnia, they can't go to work, they can't take care of the kids, they don't want to miss school. They would take the risk of not getting the vaccine and avoiding the virus. So think about 30% non-conformity in taking a vaccine because of fear of adverse effects. This is why, with Moderna and Pfizer, this is a force amplifier. It actually amplifies the efficacy and gets more people to take your vaccines.

    But vaccines, because of their hyper-selectivity and because of the ability of these viruses to avoid vaccine efficacy, it really means to me that we should think about this in a wholly new way. The immune system is so much more complicated than what conventional medicine thinks.

    When you do bioguided fractionation — and we did it with agarikon — I can tell you the active molecules we found against smallpox: inotodiol and de-sulfuric acid and ferulic acid. These are polyphenols, ethanol-soluble, not very water-soluble. The mycelium of agarikon has those three. When we tested those molecules individually, they didn't have the same effect. We found active constituents through bioguided fractionation. You take a natural product, you go from highly polar to non-polar — water being polar, hexane being non-polar — and you go down to basically a decision tree and test each one: is the potency against viruses increased or decreased? Then you elaborate this down to a single molecule. That's called bioguided fractionation. That's where the majority of our medicines have come from. Now we have AI, so it accelerates it.

    But you can bio-fractionate into inactivity, because think about all the receptors that are cross-talking. This is what I really believe: our immune system is like a sophisticated computer of natural intelligence. When you ingest something that it recognizes as being helpful for the whole system, there's cross-talk between these receptors and the immunological landscape that's saying, "Okay, open up your receptors, this is going to be helpful." I know I'm waxing a little bit into the complexity and the entourage effect, but nevertheless, we are seeing this to be true.

    We've only tested less than 0.1% of the fungal species that are out there. We will have, from the intelligence of nature, some very powerful natural products that are still in our library of potential medicines that we haven't even explored yet. I think molecular medicine is fantastic. I'm not throwing it under the bus. I just think there is a bridge between these two that we can increase the homeostasis.

    From my point of view, health and disease is a multifactorial equation. We have coefficient multipliers on one side, the end of which is disease. What can we do to have a force amplifier? I think mushroom mycelium is a force amplifier on the left side of the equation to make the end result on the other side of the equation better for the individual.

    Practical recommendations — agarikon, turkey tail, and dosing

    Andrew Huberman: Earlier you were describing this work on the immune system. I really feel like you're operating at the interface between natural products and traditional medicine in a way that I don't know many people are. You've mentioned many times the entourage effect. It seems intuitive to me, and I think it's starting to become intuitive to the public, especially in the wake of the pandemic, that no government, no pharmacy can give you the one molecule that's going to solve all your problems in any domain — mental health, physical. It's just not going to happen. There are things that can help certainly, but cocktails of things that work and synergize are increasingly being looked at as beneficial.

    Could you share with us — for those interested, meaning me, I'm raising my hand — let's say I feel like I'm coming down with something, a cold, I'm getting that sort of innate immune response, tickle in the throat, this kind of thing. Or I'm battling a cold or flu or COVID. What is this cocktail? Don't be bashful here. I want to try it next time I get sick. I want to know when to take it and for how long. Or is there something I should be taking continuously?

    Paul Stamets: I walk my talk, and I created my business Host Defense in order to do research. The research now is proving that our Host Defense products support immunity in healthy individuals. That's very clear. We have multiple peer-reviewed articles out. This narrative is picking up speed.

    What I do is I take Host Defense agarikon and turkey tail. These are the very same materials that we supplied in the COVID clinical trials. We cultivate them in our laboratories. We have FDA-inspected laboratories. We've had what's called no 483s, which is a pharmaceutical-grade level of laboratory for our extracts.

    Mushrooms that grow for 100 years — you can imagine agarikon is subjected to air pollution, algae, bacteria. Turkey tail mushrooms, anyone who's collected them — they're a bracket mushroom called turkey tail because they look like the feathers of a turkey. They're multicolored. It's called Trametes versicolor — versicolor means variable in color. Turkey tail has algae and also sequesters nitrogen through agrobacteria. So it's a polyculture. When you get a young turkey tail mushroom versus an old one, this is a problem with mushroom fruit bodies in general. They are parasitized by bacteria. They rot so quickly. They're contaminated from air pollution.

    One of the biggest concerns I have is mushrooms coming from China. I had someone tell me there's no pollution in China and they looked at me with a straight face. They are wedded to this concept that mushrooms from China are clean and pure. It's just contrary to my factual understanding and testing.

    The in vitro grown propagated mycelium, grown especially on grains — because epigenetically we're seeing the mycelium fermenting the rice creates a unique product — is like milk being added to Lactobacillus acidophilus. It creates yogurt. It's a fermented product. It's biotransformed. In our clinical trials we used rice as the control. Rice is not a filler. It changes the rice into this unique immunologically powerful product that does not overstimulate immunity.

    So what I do is I take agarikon and turkey tail. It's what I took this morning. Four capsules each of Host Defense agarikon and turkey tail.

    Andrew Huberman: I want to be clear to those listening — we didn't come in here to explicitly do a promotion. I just know that as people hear this information, some people will be very curious. They want to know what to do. I, for one, hate being sick. I don't get sick very often. I tend to move through it pretty quickly if I'm doing most things right, but I would love to be sick less often. What dosages?

    Paul Stamets: I cannot make medical recommendations. I can tell you what I am doing and I'd advocate people follow the science. I populate a website with my team — I have six full-time researchers, four PhDs. We've published like 65 articles amongst us in peer-reviewed literature. We curate a website called mushroomreferences.com. There are over a thousand references now, which has all the peer-reviewed articles on mushroom mycelium and mushroom fruit bodies, as well as adverse reactions — things that have been reported to be concerning about mushrooms, of which there are several reports. Shiitake dermatitis — some people get an allergic reaction to shiitake from even touching the mushrooms and touching their skin. They can have a dermatological adverse event.

    Yes, I sell a nutritional supplement product line. Why do I sell it? Because I wanted to do research. I couldn't get money for research. I applied to 10 NIH grants. We got two of them approved. The timelines are so long. But I can be an adventurous investigative researcher and I can dare to fail and not suffer lack of tenure. I own my own company. I've used my company and my motivation was to do research. In order to do research I needed money. So I created my intuition into a product line, and now we have the science that supports my intuition.

    I really want to save lives. What is your legacy? I want my legacy to be: "Wow, he was on the edge. He was an edge runner. He was way out there, but damn it, he was right on some of these things, and millions of lives have been saved as a result." That to me is the legacy I want to live. Galileo had the same — he was opposed by the church. I just heard from the Vatican. A person was in the Vatican. The Vatican admitted, "We were wrong about Galileo," and now they're interested in life on other planets. This is what happens when you're pushing the envelope. But we need to have credible facts to support the arguments, because hypotheses become theories become actionable solutions. That's why I'm in applied mycology. I want actionable solutions.

    Andrew Huberman: Do you take it going into an infection and through it and through the other end, or is it a daily regimen for you?

    Paul Stamets: Great question. Prophylactically, I up my regimen prior to public contact. My partner and I live on a remote island in British Columbia. We live a surprisingly extremely quiet life, and then we're thrown into the vortex of the public. Before we go, we start upregulating our immune system by taking agarikon and turkey tail. Also, I'm getting older, so my immune deficit is increasing and I want to upregulate my innate immunity. So I take it several days prior and during the duration, and then I back down to more of a therapeutic dose versus a regimen of maintenance — those are two different things, often times a four-times difference.

    Pandemic risk, H5N1, and the case for natural immunity

    Andrew Huberman: Thank you for sharing your deeper and larger motivations. Your sincerity comes through. Your commitment to these organisms and how they can be useful to humans and to the ecosystem comes through with sincerity.

    I realize you're embedded in a context and an ecosystem of other scientists. I asked about the actionables because some people will want to do this and some people won't, and that's fine. I will say, just as a brief editorial on the scientific process — having had NIH grants and sat on NIH review boards for more than a decade and saw what that process is like, how it can serve and how it also has flaws — I think any scientist, NIH-funded or not, will say that there are flaws in the system. Having a variety of ways to explore really good questions, which always requires funding, is critical to evolving the scientific and therapeutic landscape. Nowadays, because of the pandemic and because of the internet, I think there's a deeper and larger appreciation for people taking a variety of approaches to exploring questions. You and your colleagues were early to this approach, and I just want to second that approach as somebody who also respects the traditional approach.

    Paul Stamets: We should be collaborative. My best supporters have been my skeptics. They've taken me to the mat and I go, "Okay, where's the peer-reviewed articles? Here they are. Where's the double-blind placebo clinical trials? Here they are. Next question." And they have to face whether they actually have a prejudice. They were demanding this before, and now we've delivered it. Why are you in denial that natural products can be helpful for the immune system? It becomes a point where there is a scientific bias. Most good scientists — and this is why my best supporters have been my skeptics — many of my supporters in the bio defense program feel vindicated for supporting me now because they've seen the clinical studies.

    I don't want to be alarmist, but let me mention something that's really important for your listeners to understand. COVID is not the last pandemic. In Washington state right now, two dairy farms are in quarantine because of H5N1, bird flu. Bird flu has jumped to 90 mammal species — 90. Killing seals, sea lions, all these birds you know about, but also killing marmots and all sorts of other mammals. And the fatality rate of H5N1 if it hits humans is about 40 to 50%. That's going to make COVID look like a minor viral pandemic. The fact that it's jumped from birds to now 90 mammals is a warning bell.

    The virologists that I know who are involved in bioweapons defense — and just three weeks ago the heads of AI platforms said the biggest threat to humanity's extinction is bioweapons being engineered by artificial intelligence. This is the inexpensive bioterrorist weapon: to create a viral pandemic with specificity. This is something that we should all be concerned about.

    This is why I believe in natural intelligence upregulating natural immunity, because your sophisticated immune system has the wisdom to be able to create the antibodies to protect the host — the system, you — because of this microbiome that we've come from, with the mycelium and this plurality of individuals who are unified to protect the system. You are a natural product, are you not? And natural products being used with each other is the lesson of evolution. So it should be all hands on deck.

    I am so honored that a medical foundation with virologists and scientists looked at all of our data, and in collaboration with a well-known university here in California, has awarded us $2.6 million to look at every strain of agarikon we have — 130 strains — for hyper producers. We want to find a Mary Hunt strain against H5N1, like she found with Penicillium chrysogenum. So we have this library, and if there's anything I can communicate irrespective of me, irrespective of any ego or money, the investment in biodiversity is an investment in our biosecurity. These are rivets of an airplane. How many rivets will we lose before the system dismantles?

    Now we have factory farms, unprecedented transportation of individuals. One person on an airplane with Ebola — they had to test 200 people because he was on an airplane really sick. The tracking of Ebola because of the infrastructure has gotten out of control. We have so many potential viral pandemics. And the other thing people may not understand is you can co-incubate multiple viruses and then you get horizontal gene transfer. The bacteria that are also growing can become a platform for horizontal gene transfer. We are in unprecedented times of population density, transportation, factory farming, and now AI and terrorists who want to create Armageddon.

    What I'm offering is a platform, a foundation to elevate conventional medicines to a higher state of efficacy. We have to prove it. But for instance, I published in Nature Scientific Reports with my colleagues on reducing viruses in honeybees — up to 14,000 times less viruses in honeybees in 10 days. The deformed wing virus is a pandemic against beehives. Apis mellifera, the honeybee. My colleagues at Washington State University, some of my employees, and other scientists from the USDA — Jay Evans is a co-author, he's a renowned virologist, he's never seen anything work so well. We were able to do the extracts of these polypore mushrooms in the sugar water and give it to them, and in 10 days it had a 14,000-times reduction in the viral titers. The deformed wing virus — the wings become weakened, they deform, and bees used to fly for seven to ten days and now they're flying for four. One bee pollinates a thousand flowers a day. Think about 4,000 to 5,000 fewer almonds and cherries and apples. It's a threat to biosecurity. We are in a bee apocalypse right now — the worst die-off of honeybees in the history of this area.

    We met with the FDA and we've been trying to get this approved. Number one, they don't want to hear about viruses. I actually had an FDA regulator on Zoom look at me in the eye and say, "Okay, we want you to characterize all the constituents inside this natural product." And I said, "May I say something?" She said, "Yes." I said, "There are more than 200,000 constituents in this product. You want us to characterize every single one of them?" And she literally couldn't say anything for about 45 seconds.

    You take a pharmaceutical that's 99% pure. The impurities are less than 1%. So that modality of thinking — that you want to test all impurities, what's the active constituent — this is where natural products face this huge barrier of regulators. You cannot get these products to market because a bureaucrat in Europe has outlawed the selling of mycelium because they say it's a novel food. But mushrooms are made of mycelium. So one regulator makes a decision that denies Europeans the ability to buy agarikon or turkey tail mycelium for pandemic defense.

    Psilocybin — history, legality, and categories of risk

    Andrew Huberman: There are some parallels within the realms of physical health and mental health tools that are purely behavioral. I'm 51. You're about 20 years older than I am.

    Paul Stamets: I'm 71.

    Andrew Huberman: All right. So you and I can remember a time where if somebody meditated or did what would now be called breathwork, or did yoga, or lifted weights for that matter, they were part of an extremely niche community that was either ridiculed, ignored, or just considered fringe. Now, having had the 80s, 90s, and early 2000s with tons of studies, and now even more studies on the benefits of resistance training, meditation, breathwork, yoga — and now actually great work from Chufu Ma's lab at Harvard is showing that acupuncture and its specific arrangements of needle and pressure points can liberate certain molecules and there's mechanistic understanding — now everyone goes, "Oh yeah, meditation can help make you more calm, more focused." But not but 10 years ago, that stuff was considered pretty wacky. I feel like things are shifting toward the better.

    Paul Stamets: We're left coasters. We live on the West Coast. There's always resistance to change. I am a blend — I'm socially liberal, but I also come from a farming family of wheat growers. We have thousands of acres of wheat in my family. Talking to my relatives who are farmers, any potential change from the system is very dangerous. Their margins are so thin, they can't risk change. "Let the scientists do that and then prove it and then give us a new deliverable that we are confident in." It's just natural for a conservative scientist even to resist change. They have to worry about reputation, tenure, and failure.

    This kind of segues into my psilocybin experience. When I first went to these academic conferences interested in psilocybin, two things happened. One, it was like I was a leper. There was a force field. I'd walk into a crowd and the force field would distance themselves. Here comes the hippie interested in psilocybin. It was extraordinary. I refuse to be an apologist for my interest in psilocybin. And now it's a revolution sweeping the planet. There's a revolution from the underground. 2.5% of Americans admitted they used psilocybin last year.

    Andrew Huberman: Microdosing or macrodosing?

    Paul Stamets: Both. That's over 8 million Americans by my calculations. Do you think this is because of the studies on repeated use of psilocybin as beneficial for major depression?

    Andrew Huberman: Yes. The clinical trials for people who are depressed, PTSD, all sorts of other conditions — and then increasingly there is evidence that psilocybin increases neuroplasticity and creates new neural networks. That's the area we have focused a lot of attention on. Other scientists are now also showing the same thing.

    The observational studies — and this is easily discoverable, anybody can search the web for this — show statistically significant association of induction of calm with a person who's done one dose of psilocybin. Partner-to-partner violence: two heroic doses of psilocybin. 90% of people addicted to tobacco compared to the nicotine patch, one year later not smoking cigarettes.

    Can you define heroic dose?

    Paul Stamets: Let me define it several ways. For those of you who know Psilocybe cubensis, the golden tops — that's the most commonly cultivated psilocybin mushroom in the world, super easy to cultivate — that typically is over 2.5 grams. Really, the hero's journey is around four to five grams. This is where set and setting is so important. You have therapy afterwards. It's so important that people don't — you say before, during, and afterward. Preparatory is really important. There's a great nonprofit in Canada called Roots to Thrive. Dr. Pamela Kryskow is one of the co-founders of it. They really have a lot of experience with end-of-life, permitted by the Canadian government on a case-by-case basis.

    Andrew Huberman: We should probably touch on legality and we should touch on categories of humans for which there could be elevated risk. As far as I know, psilocybin has been decriminalized in the United States in a few places, but is still — I have to pronounce this very clearly — illegal to possess or sell. That's my understanding.

    Paul Stamets: Absolutely. Very important. If you cross state lines, you're involved in interstate transportation of a Schedule I drug. Possession of it is federally illegal. Transportation across state lines is very federally illegal. Oregon and Colorado have decriminalized. I've spoken in front of two city councils in Washington state, and there was unanimity of the city councils to decriminalize the possession of psilocybin to the lowest priority of law enforcement. They made it less of a violation than a parking ticket. So they decriminalized it — didn't legalize it. Olympia, Seattle, Mount Vernon, Port Townsend.

    Andrew Huberman: What about categories of risk?

    Paul Stamets: People who have a genetic or familial or other predisposition to psychosis or bipolar disorder need an abundance of caution. This is very, very serious. They need to be pre-screened. We need to have adults in the room on this. This is not a party drug. This is serious medicine.

    70% of people typically have a positive experience. The Compass psilocybin studies are showing about 40 to 45% resolution of treatment-resistant depression or major depressive disorder. It's clearly a very powerful medicine — doesn't work for everyone.

    Very interestingly, Johns Hopkins, Roland Griffiths — who unfortunately passed away, he really led the charge on this — they had a retrospective study 14 months after heroic doses of psilocybin. They interviewed the individuals, and as I remember, about 70% of the individuals described it as an extremely positive experience, in the top five positive experiences of their life. 30% of the people described it as a difficult experience.

    Andrew Huberman: But the 70% of the people, 14 months later, determined that the act of re-remembering the experience was psychologically beneficial.

    Paul Stamets: They relived the experience. Well, that's reliving a neural pathway and a memory. The 30% of the people who had a difficult experience — there were no adverse effects post the experience. 14 months later, they just said, "Not for me. I'm not going to do that again. That was too difficult."

    So people with schizophrenia, psychosis — absolutely, this is truly a mind-bender. But so many people can benefit from this, and people need to realize this is the anti-addictive drug. So many people when they take a high dose of psilocybin, they look at the mushrooms the next day and say, "No way. I'm not touching those." Many people use it one time in their life. One time. Think of that. This is why for opioid use disorder, for tobacco, for alcoholism, for all these addictive behaviors, for obsessive-compulsive disorder — which is what we're involved in right now — this seems to reprogram not only the neuroscape, but we know there are dendritic tips being formed from the tips of the axons. When these dendritic spines grow out and the adjacent axons touch each other, you have synaptogenesis and then neuroplasticity of a new neural pathway. You have another way of breaking your addictive behavior because you're not stuck in a rut. That's what's so exciting — the neuroplasticity benefits of psilocybin.

    Everything we're doing right now, Andrew — seeing or listening or elocuting, me trying to formulate thoughts — is all based on the health of our nervous system. I think psilocybin will go down as a paradigm-shifting drug rediscovered that could have the most dramatic impact for the health of individuals in society of any medicine discovered in history.

    Directed plasticity, therapy, and the oceanic experience

    Andrew Huberman: That's a big statement. I spent some time with the clinical trials on psilocybin for major depression and a little bit on the data for OCD. I should point out we're not talking about OCD of the "this person is really nitpicky" variety — we're talking about people whose compulsive behaviors actually strengthen the obsessions, and that's a vicious loop. It's very detrimental to everyday living. So if these things can provide relief, and the clinical trials are very encouraging, I'm on board.

    I do have a question. Mechanistically, we know that psilocybin can create new neuronal connections in the brain, maybe unmask existing connections as well. I've been intrigued by the paradox where plasticity is great, but directing the plasticity toward a particular endpoint — the resolution of the depression, of the obsessions, of the excessive ruminations — that's the goal. It's not plasticity, it's directed plasticity. And there I feel like the qualified therapy plays a critical role. It's not clear that people can just freestyle this.

    So the big question in the psychedelic therapies realm is: is the experience of the psychedelic — the thoughts, the unusual perceptions compared to everyday life — is the therapy, what we say and what we hear, what we think and what we feel during those psychedelic sessions, critical to the clinical outcome? Because ultimately there's also a lot of neurochemistry happening that facilitates plasticity. I think if people are going to use these powerful compounds to try and be healthier, it's going to be really important to figure out what should they be asked during these sessions. I don't think any of that is standardized.

    Paul Stamets: Absolutely. It's so important. Let me just bring it back from my perspective. My father — who was anti, he was a pro-Nixon anti-drug guy — in his 70s said, "Paul, how long do mushrooms stay with you?"

    Andrew Huberman: How old was he when he said that?

    Paul Stamets: About 74. I was blown away. He never — but the mushrooms somehow were different to him.

    The father considered the father of American mycology, Alexander Smith, also in his 70s, published a monograph on the genus Psilocybe. It contains most of the psilocybin mushrooms, and he studied psilocybin mushrooms all of his life but had never eaten them. He asked me, "Paul, I trust you. I want to do psilocybin mushrooms with you." I have two father figures who asked to do psilocybin mushrooms with me, and I turned them both down. I turned them both down because I knew the therapeutic element was so important.

    For listeners who haven't had this experience, you have what can only be best described — we lack the words for this — as this oceanic experience where you suddenly feel the ego dissolve and you feel connection with nature and the universe. You realize you're just a whirlpool of molecules that have formed into this body, and before you were born you didn't exist, and after you die you don't exist in the same form, but this unanimity of being connected to this big concept. We can argue about what name to put on this concept or what this force is, but this oceanic feeling is a high predictor of resolution of PTSD and depression. The individuals who don't have this oceanic feeling seem to correlate with not having as many benefits.

    Therapy helps you. The reason why I turned down my father and Alexander Smith is that the next day, literally, I was leaving. I asked both of their wives, "Will you also take psilocybin mushrooms with us?" Both of them said no. I didn't want to be the wedge in their relationship — someone who has the most spiritual experience of their life and the other person has no idea what they're talking about, and then I disappear. You have to have a therapeutic support team.

    This is what Roots to Thrive does. Their program is up on the web. I highly recommend people look at Roots to Thrive and look at their model. They do group therapy, six to eight individuals. It started with end-of-life anxiety, typically stage four cancer. It's been much bigger than that now. But you end up with a community of souls — people that you learn from prior to the experience, and then after the experience, they have new friends, new colleagues, a community of people who they can talk to.

    So many physicians — you walk out of their office, you're the patient. Goodbye. And the patient goes, "Wait a second, I thought we were friends." No, you've always been a patient. The Roots to Thrive model is a foundation for being able to economically and efficiently create talk-therapeutic benefits, not only with a trained therapist but with individuals who have a shared common experience and feel a new relief. So many of the patients in Roots to Thrive have become the therapists to their family, saying, "I'm dying." And the family's going, "What's going on here?" Before they were anxious about dying, and now they're saying, "Family, chill out. It's okay. I know what's going on here." And surprisingly, many of them are not dying.

    No clinical trial has been done on this, but when you're happier, your immune system upregulates. When you're depressed, you have an inflammatory state, your immune system downregulates. So it's mind over body — clearly it has an effect here. The therapeutic element that you mention is absolutely critical. This is why again I want to say we have to be adults in the room about this. These are powerful medicines. These are not party drugs. We need regulation. It's surprisingly coming from me, but we need regulation. The dangers of not having regulation and purity and this therapeutic regimen — we don't want to fumble the ball on this. It's too much potential good for society.

    Psilocybin, politics, and the path to rescheduling

    Andrew Huberman: Well, I'll just say — and here I want to be clear, I'm revealing my personal bias, but with all the cautionary points that came up earlier in mind — amen to that. It's kind of ironic that the fastest movement we've observed for the psychedelics — in particular ibogaine and psilocybin presumably will be next, and the non-psychedelic empathogen MDMA moving to FDA approval, they're not there yet but it seems like they're headed there quickly — has been through this alliance between, let's just call it what it is, the left and the right. It's been, as I now refer to them, the Ricks: Rick Doblin of the MAPS Initiative and Rick Perry, former Republican governor of Texas, joined arms in this, and things are moving pretty quickly. Who would have thought that during a Republican administration, psychedelics would get accelerated toward the FDA finish line?

    Paul Stamets: And they have not crossed yet. So I say this with optimistic anticipation, but it's really this bipartisan effort that has really made it happen. I don't think the Republicans could have done it alone. And I don't want to speak for Doblin, but I don't think the left could have done it alone. It really feels like there needed to be, sadly, a mental health crisis and then the exploration of these medicines to get us here.

    I think in 2027 we're going to see at least one of the three medicines I mentioned go to Schedule II, Schedule III, Schedule IV as soon as possible. But what you're speaking about is that most all of us have families of diverse opinions politically, religiously. My mother was an arch conservative. She was a deeply devoted Christian. And I learned that in Christianity and Judaism, there are psychedelic Christians now who do one dose of psilocybin and feel like it affirmed their religious beliefs — they don't have to do it again.

    I think psilocybin makes nicer people. It makes us tolerant of each other. We have so much more in common. 95% of us have the same common beliefs. It's social media and these bots and clickbait that exploit people getting pissed off or excited or falling for it. This is really monetized and brings out the worst in society. And I think what happens with psilocybin is this is a reboot of the system.

    Most of us have had family members or friends who've been afflicted with the opioid pandemic. The vets coming back with PTSD, having these heroic doses and then seeing these people change — it's good news. It's a pebble in the pond of positivity. When you see somebody heal and you can champion their cause, you become a cheerleader. Like Rick Perry — he sees the benefit and says, "What was I thinking?" And this is where it crosses the political divide.

    I can't help but say it's ironic that during this administration they had the courage to do something that the previous administrations knew they should have done but, because of political blowback, were afraid of losing their base or losing a few votes. So we're at a new day, and I hope that this never goes backwards.

    When you look at these studies, there's therapeutic use of psilocybin for treating people with mental health or psychiatric disorders. We're all kind of on the spectrum. We have good days and bad days. A family member dies — it's a tragedy. So we all sort of are moving back and forth in this emotional psychological spectrum. But what about all of us normals? What about prevention of addiction, prevention of PTSD, prevention of depression?

    I'm going to say something very controversial, but I absolutely believe it to be true. When you look at the cost-benefit ratio of preventing crime, preventing violence, preventing depression, addiction, PTSD — psilocybin mushrooms should be available for everybody for free, because the return on investment to society, in the many billions and billions of dollars — the recidivism, the reduction of the number of people going to courts and prisons — this is a huge paradigm-shifting potential breakthrough for society. It just makes more congenial, nicer, and I believe more intelligent people. We have a crisis in creativity. We have a crisis in immunity. This is where this subject field is so exciting to me.

    There are 306 clinical trials on psilocybin at clinicaltrials.gov as of this morning.

    Andrew Huberman: 306. That's impressive. Do you know the IRB boards? Every one of them had to go through an IRB board.

    Paul Stamets: Yes. There's an institutional review board to make sure that there are safety measures in place because these are human clinical trials. Lots of pre-clinical animal data as well as in vitro data.

    When I say that psilocybin mushrooms should be made free, at the same time my sister would never take a psilocybin mushroom, but if it was approved by the FDA and was a pharmaceutical and she needed it, she would take it. So there's universality of use. There's plenty of people for both the pure pharmaceutical as well as the natural form. But I think we do need to have intelligent regulation by the government. We need to set up programs.

    In Europe, for instance, all pharmacies and all pharmacists are trained to identify mushrooms. When you want your mushrooms identified in Germany, you go to a pharmacy and they're trained on identifying the best edible and the best poisonous mushrooms. That's kind of what we need. We need that sort of infrastructure — where you want to do this, okay, we have a week-long therapeutic program, enter this, then you'll be given it and you'll have follow-up, etc. And so many people, it's just a once-in-a-lifetime experience. If you could improve your life for the rest of your life, and it takes four to five hours — the investment in making your life fundamentally better for four to five hours of investment is just a massive return.

    Microdosing, the Stamets Stack, and psychomotor benefits

    Andrew Huberman: As far as I know, the studies are only on adults. I don't know of any studies on younger folks, younger than 18. I'm going to just put out a voice — not to protect me but to protect whoever's listening and watching — the brain is very plastic early in life. Growing up is a psychedelic experience. I'm yet to be convinced that psilocybin has been shown to be useful in young folks. I'm not saying it can't be. I'm just not aware of any good data that would argue that people younger than 18 should run out and do psilocybin.

    Paul Stamets: As an abundance of caution, it's responsible for us to say that psychedelics are not for everyone, and for very good solid reasons. However, indigenous peoples all over the world have a common tradition of using psychedelics — peyote, psilocybin — with younger people, especially at the coming of age. And Rick Doblin has talked about this with his meeting with the FDA. They are emphasizing that MDMA, not only for couples therapy and resolution of depression, but prevention and treating younger people early on in their disease cycle could really make a difference later on in life.

    Andrew Huberman: More studies would be helpful in my mind. Can I ask about microdosing? I call the macro the heroic dose — you refer to it as a heroic dose — two to three grams in many of the clinical trials, done once or twice with therapy. Then there's the heroic doses of four to five grams. What is a microdose? What qualifies as a microdose? Is it less than a gram, and how often are people taking them? I'm aware that you were involved in a study of microdosing — a self-report of positive and negative effects. Maybe you could summarize that study and tell us what constitutes a microdose in terms of milligrams and frequency.

    Paul Stamets: Everyone's different and everyone has different sensitivities. A microdose by definition is subsensorium — below the level that you feel an effect. That's what a microdose is. In the Psilocybe cubensis scale, one gram at 1% is 10 milligrams. 10 milligrams clearly is a liftoff dose. A microdose is usually one to three milligrams, something like that for most people, normalizing across the landscape. People can feel 10 milligrams.

    Andrew Huberman: Of the pure psilocybin?

    Paul Stamets: The pure psilocybin. Okay. That would be one-tenth of a gram. One gram would be 10 milligrams. This is very important. One-tenth of a gram is 1 milligram. One gram is 10 milligrams. The hero's journey starts at 2.5 grams or 25 milligrams.

    Andrew Huberman: What is a micro versus macro dose in terms of the actual mushroom or broken-down mushroom product? Not the pure psilocybin, but the mushroom itself.

    Paul Stamets: One-tenth of a gram versus 5 grams. One-tenth of a gram is 1 milligram. One gram is 10 milligrams. 5 grams is 50 milligrams. The FDA has approved 25 milligrams, or 2.5 grams of mushrooms, as the standard dose. That's why most all clinical trials are 25 milligrams. 2.5 grams is largely given at 1% concentration.

    Andrew Huberman: So let's just highlight that last statement. They are 2.5 grams of Psilocybe mushrooms at 1% concentration, which is 25 milligrams. So when people hear 25 milligrams or 2.5 grams, that's an enormous difference. They're talking about the actual mushroom versus the chemical in the mushroom.

    Paul Stamets: Now realize that 99.9% of the uses of psilocybin is in psilocybin mushrooms. Just a few hundred, maybe a few thousand people now have taken psilocybin the molecule. So the real-world use of psilocybin is in psilocybin mushrooms, which has all these other tryptamines involved. So there's an entourage effect.

    We published — Dr. Pam Kryskow and colleagues published a paper on four individuals who took both psilocybin the molecule and psilocybin mushrooms in their natural form or an extract thereof. They interviewed them, and all of them preferred the natural form. The pharmaceutical had a quick liftoff. It felt chemical and then had a quick descent.

    Andrew Huberman: Sounds like most pharmaceuticals.

    Paul Stamets: The psilocybin mushrooms had a little bit delayed but also a quick takeoff. But it had a long tail, and that long tail the patients felt gave them time to reflect. Some of them reflected that they felt like they were connected with the natural world.

    When you go back to psilocybin — its lineage goes back, the molecule goes back to Albert Hofmann in 1958. When you're taking the mushrooms, you realize there could be several million people on the planet at the same time taking psilocybin mushrooms. You are taking a journey with a collective consciousness of millions of other people who are simultaneously entering into this space. Your lineage goes back centuries, thousands of years, and communities across cultures. So the sense that you're part of this community that goes back in history and is tied to nature, compared to a pharmaceutical — which is great, but as one patient said, "If I only had the pharmaceutical, okay, it works, I would take it, but I prefer the mushrooms."

    That's illustrative of where we need to go. Standardization is important because you need to be able to understand what you're taking. But just your very diet affects your sensitivity to these substances.

    So let me go back to microdosing. There's microdosing, medium dosing, and the high-dose therapeutic dose — the macrodosing. The sweet spot that we're increasingly paying attention to is medium dosing.

    Andrew Huberman: And maybe just in mushroom weight, what is that?

    Paul Stamets: Mushroom weight — that would be on the order of half a gram, which would be like 5 milligrams. If you have pure psilocybin, it's often called the museum dose. You know why it's called the museum dose? It has been a common practice for a group of friends to take a small amount of psilocybin mushrooms and then go to a museum. And you may have encountered these people occasionally. They're unusually happy. They're visually stimulated by everything in the museum and the artwork, but they typically wear sunglasses because the pupils of their eyes are so dilated that if they took off their sunglasses, it would scare people. They have no whites in their eyes. But it's called the museum dose.

    I say that because it's a liftoff dose. It's sensorium. But it only is sensorium for a very short period of time. I don't like making the analogy to alcohol, but it'd be like drinking half a cup of wine real fast and you feel a little bit of a liftoff for a few minutes, half an hour, and then it goes down. But this is not the five-hour deep journey.

    The sensorium dose we think is important because activating the 5-HT2A receptors, you're actually engaging — there are more 5-HT2A receptors in your gut, and the vagus nerve connection with the mitochondria cascade that's occurring from the vagus nerve hasn't even been explored. We're all talking about the prefrontal cortex or 5-HT2A. Psilocybin is a prodrug for psilocin. So 10 milligrams of pure psilocybin is 5 milligrams of psilocin.

    Andrew Huberman: Just to simplify — the prodrug is causing the release and activity of this other molecule, which is then the bioactive molecule. And you mentioned the 5-HT2A receptor is a particular category of serotonin receptor which seems to be the basis for a lot of the therapeutic effects of, let's just call them what they are, magic mushrooms.

    Paul Stamets: Yeah. But there's also TrkB engagement, and that's the area that — yeah, we'll talk about BDNF, the receptor for BDNF. There's more than one receptor group being engaged. But the museum dose creates a liftoff experience that's sensorium but is not intoxicating. You feel it but you wouldn't really say you're intoxicated. You just kind of feel it and then it goes away.

    Andrew Huberman: You wouldn't want to drive.

    Paul Stamets: No, but there are so many reports of extraordinary athleticism. Yesterday I heard about a person who's a professional dart player. He told me about the museum dose and he came up to me and said, "Yeah, I've been doing the museum dose. I'm a professional dart player." There are many examples of this. From martial artists to boxers to people involved in baseball, across many disciplines.

    Andrew Huberman: Don't experiment on game day.

    Paul Stamets: Well, isn't this the golden rule around all substances and performance — you don't want to compete under conditions different from those in which you practiced. The best competitions tend to emerge under similar conditions to which you practiced.

    Andrew Huberman: I get your point that it maybe is allowing people to access a plane of mental and physical performance that they couldn't otherwise.

    Paul Stamets: Well, you've developed muscle memory in skills. Once you develop those skills, there are psychomotor benefits enhanced by psilocybin becoming psilocin and binding with these receptors. We know that visually you have a lot more information. Hearing seems to improve. Those of us who have done psilocybin mushrooms — the colors, everything lights up. That's because you're seeing more of the spectrum. You have more neural activity. And it's not artificial. This is the thing that's weird. Back in the day in the 60s and 70s, psychedelics were thought to make you see a non-reality, something that doesn't exist. Now, most of us believe you're seeing reality in a better way and more clearly than you've ever seen it before.

    Andrew Huberman: As a neuroscientist, I think we should highlight what exactly that means. Our sensory apparati — our eyes, our ears, our touch receptors in our skin — are extracting a pretty narrow wedge of physical information in the world and then creating these abstractions in our brain of what's out there. On psilocybin there may be a wider wedge in certain domains and an integration of different senses. Certainly there's more perception at the level of overlap between the senses. Some people experience synesthesias on psychedelics — I certainly have — where you touch something and the contour of that surface matches to particular frequencies of sound. That's not uncommon. It's a form of synesthesia.

    May I ask about the benefits and any potential side effects that were observed in this study on microdosing? I know it's one of the few large subject-number studies of microdosing and I know you were involved.

    Paul Stamets: Yes. My colleagues at Quantified Citizen out of British Columbia — I think we got up to 25,000 participants. We published two papers in Nature Scientific Reports, observational studies. These are self-reporting. They enrolled, created a baseline, and reported the motivation for why they were taking psilocybin mushrooms, how much they were taking, what they were combining it with, etc.

    The first paper we published in Nature — we heard back from the editors that what they really liked about it was that the two groups were so well weighted. We had more non-microdosers than we had microdosers in the study — 4,500 or so non-microdosers, a few hundred less microdosers. People were motivated to do a test, and we had more non-doers. I thought, well, maybe they're trying to create their baselines. But of course the results showed tremendous improvement against depression and PTSD and anxiety — those are the ones that really were significant in the measurements.

    Now the blowback is expectation. You're in a community of individuals sharing this experience. How does expectation factor in? Well, every medicine has a coefficient factor of expectation. You go to a doctor expecting to get a treatment. So you feel confident in the —

    Andrew Huberman: The placebo effect is real.

    Paul Stamets: So yeah, the placebo and the nocebo effect. What was really interesting is I intuited that we could enhance psilocybin's benefits if we bundled it with niacin, because psilocin is a vasoconstrictor. Niacin is a vasodilator — vitamin B3, the flushing form. Vasoconstriction neuropathies often present themselves as deadening the fingertips and the toes because of vasoconstriction. The neurons get starved of blood and they atrophy.

    So I thought the flushing form of niacin — when you take it you feel itchy, you get red, it's a vasodilator — if you're going to offset neuropathy, why not have a vasodilator with psilocin, which is a vasoconstrictor? So you get more blood and more psilocin to the endpoints of the peripheral and the vascular nervous system.

    So I came up with something called the Stamets Stack, and I named it after myself. Doctors can name diseases after themselves. I named it after myself. I was tired of getting ripped off. So many people would take my ideas, rip them off, and they wouldn't ever give me credit. So I'm just going to tag this thing. The Stamets Stack is psilocybin or psilocin, niacin, and lion's mane mushroom mycelium.

    In this Nature Scientific Reports study on microdosing, there was significant measurement of increase in mood and decrease in depression and anxiety. But we were criticized that this is all the placebo effect of expectation. So I asked my colleague Dr. Pam Kryskow, "Don't we have something that's not related to expectancy or is outside of this argument?" And she said, "Yes, we have the psychomotor test, the tapping test. How quickly can you tap your two fingers in 10 seconds?" So we put the tapping test in the microdose app that people could then measure.

    What was amazing is that compared to non-microdosers after 30 days — and there was a learning period for a few days so you could practice — the people who took psilocybin at a microdose level, again we're talking a tenth to a third of a gram of Psilocybe cubensis, and those people who did the Stamets Stack — in 30 days the tapping frequency for the stackers went from 43 to 63. That's a psychomotor benefit. You can't say that expectation increased the tapping frequency. That really struck me. Oh my gosh, this helps your nervous system. Think about walking. Think about typing. Think about playing guitar. Think about a teacher trying to play the piano when they're older. Think about not falling going to the bathroom as you get older. I thought, this could be just a neurological tonic that can help improve your basic neuroscape.

    Now unbundling this — is it the niacin or is it the lion's mane? I'm increasingly thinking that niacin is a force multiplier. Ironically, at clinicaltrials.gov, of the 306 clinical trials, there are at least 20 that use niacin as the active placebo — teaching oppositely from what I'm advocating — because the flushing occurs in 20 minutes. They wanted to make sure some people felt something. So it's people sort of teaching away from what I'm advocating. But I think niacin is an amplifier. I think lion's mane also adds another dimension to this for remyelination. The dendritic spines that are being formed — I think they're augmented with niacin. I just think there's more blood flow, and it just makes sense to me that niacin would be an amplifier to help psilocin be more neurologically beneficial.

    Lion's mane, cordyceps, and cognitive enhancement

    Andrew Huberman: That brings us to cordyceps and cognition and memory. Could we talk about cordyceps and lion's mane? I get asked about these quite often and have since the beginning of this podcast back in 2021. Some of the earliest questions were: when are you going to talk about cordyceps? When are you going to talk about lion's mane? When are you going to talk about reishi? Let's constrain this walk as we say, because this is a vast discussion. What are some very top-contour statements that you feel comfortable making about the role of fungi in improving memory, cognition, and some basic known mechanisms? Now we're not talking psychedelic mushrooms — we're talking cognitive enrichment of some sort.

    Paul Stamets: I would refer people to mushroomreferences.com. There are peer-reviewed articles. Cordyceps is really a big bucket because there are multiple species, and this is a really cool story in many ways. It turns out that when they did DNA amplification, they got five different species coming out of Cordyceps sinensis fruit body in the Himalayas. When they cloned — these scientists were good, they knew what they were doing — they would take a Cordyceps stroma, break it, take a piece of tissue inside, put it in a petri dish, and get this fungus to grow. "Oh, I got cordyceps." Well, that's true of the oyster mushrooms, that's true with shiitake, it's true of the agarikon. But it turns out that in this stroma there are multiple species of fungi that are coexisting. One of them was Cordyceps sinensis. Then it became Ophiocordyceps sinensis. Another one's Hirsutella sinensis. The other one is Paecilomyces hepiali. So you kind of had this war going on of mycologists saying, "I got the real cordyceps." "No, I got the real cordyceps."

    Cordyceps militaris is also another cordyceps that's much easier to grow. The problem with Cordyceps sinensis records is that we don't know which cordyceps we're actually studying. What we do know is that it increases adenine and oxygen uptake. The study that's most believable — I think about 73 patients with Cordyceps militaris — they primed themselves for two to three weeks and it increases the ability to perform. So they're taking cordyceps at gram dosages.

    Andrew Huberman: Is time of day relevant here?

    Paul Stamets: I can't speak to that. I don't think it happens that fast. I don't think that happens that fast. With reishi mushrooms and sleep — I think that does happen. Reishi mushrooms can enhance your quality of sleep. Lion's mane mushrooms also — cells take time to divide. This is why the heroic dose of psilocybin versus titrating it with medium doses — if it's going to be neurostimulatory, it can't be one spark and that's the end of the story. I do a lot of cell culture work, and then my grows look like neurons. I always thought, wow, these are like neurons. But it takes time for those cellular divisions to occur.

    Clinical studies are very expensive, and what's the motivation for a clinical study if you don't have protection of IP? Who's going to make the investment? So it's very difficult to find phase two studies. There are several phase one studies. They cost $500,000 to $2 million a piece typically, depending on the cohort and the size and what they're doing. They're safety studies. The phase two studies looking for an effect are in the $5 to $20 million range. There's a lack of funding. There's not the vehicle of profitability and investment in intellectual property to get these studies funded. So the lack of studies should not impugn the potential effects of these. It's just a fact that the economic landscape does not support natural products research to phase two and phase three.

    Artemisin came from Artemisia, active against malaria. That's a great example of a natural product that did make it through clinical trials. So lion's mane and cordyceps — it takes time for these effects to be seen. Oxygen intake and performance enhancement occurs over time. It's not an immediate thing.

    Andrew Huberman: I'm grateful that you pointed that out because I think a lot of people have encountered products where they have cordyceps and will take it thinking there's going to be a cognitive-enhancing effect. It makes perfect sense to me now why in many cases it wouldn't have that acute effect, but when taken continuously for some period of time might upregulate brain-derived neurotrophic factor. The blood flow argument that you make about niacin makes tons of sense. Everything we know about the cognitive-enhancing effects of exercise are both acute — because of the increase in alertness which allows us to focus, as well as the improved blood flow and cerebrovascular effects — and longer-term. So the notion of blood flow, delivery of chemicals, and neuronal activity all jibes.

    Mycelial electrical signaling and the neural network of nature

    These days you can find a lot of chatter on the health internet and a few studies on things like grounding — putting feet on the ground, electrical grounding, magnetic fields. As somebody who's deeply embedded in the research on and practices of circadian biology and sunlight, to me it's not that wacky, but we need more data. I'm very interested in how fungi might have electrical signaling both between each other and with other organisms, meaning us. I'm fascinated by this idea that there are electrical fields being passed laterally but also to other organisms through these fungi.

    Paul Stamets: I postulated that mycelium will be microcomputers in one of my books in 2004, Mycelium Running: How Mushrooms Can Help Save the World. I was lambasted by the critics and skeptics. Now we know there are 50 word packets — discrete word packets of electrical signals — that have been discovered signaling through mycelial networks. They are conductive. They hyperaccumulate heavy metals. We know these are electrical signals passing that alert the mycelium to food, to predators. We don't know exactly what all the words mean, but they're distinct word packets. Anyone can look this up. We know 50 immediately. Do the algorithm — how many potential sentences can you create? So we know this signaling is going on.

    I think we are in constant biomolecular communication with our ecosystems. The mycelium being an externalized neural network — I described it as not only a neural network of signaling, which we know now to be true, but it's externalized lungs, because they're exhaling carbon dioxide and inhaling oxygen. They're externalized stomachs because they digest our nutrients externally. This is a very efficient structure for accomplishing three things.

    Our neuroscape and that of the neuroscape of mycelium — I think this is the future. I have just been in communication with one of the owners of Clark Shoes. We started jamming on these ideas. The idea we started focusing on is: since every footprint that you take, you're stepping on literally hundreds of miles of mycelium — if you could create a neural net interface with your shoes, and then with mycelium-like garments and with hats, you then become these neurological membranes that are connected with nature, both for weather systems and for contact with celestial signaling, gamma rays from a galaxy. What I'm just saying is that you could extend your neural sensitivity networks by using mycelial interfaces. The idea of being able to walk across the landscape and have neurological communication with the ecosystem around you — it's actually happening already.

    The mycelium, I strongly believe, is sensitive to every footstep that we take. It knows that you are there. And why wouldn't it? You break a twig, there's competition of the mycelium to grab that twig to digest it. Competition is a good thing, especially with a diversity of fungi trying to grab more nutrients. So it just seems to me de facto to be true that these neural networks and the mycelial networks are constantly in communication, constantly in competition.

    What if we start seeking alliances with these mycelial networks in nature? What will that do to expand our consciousness of nature and tapping into the deep intelligence of these mycelial networks? This is where AI could come into place. Obviously, if it's raining, it's going to be more conductive. How would the membrane be? Would it be copper meshes? What would the interface be? This is just the beginning of this idea. There are lots of young scientists who could take this idea and run with it.

    We know these mycelial networks are neural networks. Now, it sounded crazy back when I described it. Now other scientists are saying yes. It's funny — I do take some pride in the fact that a lot of my ideas that were very fringe are now considered to be accepted science.

    I want to share something with you. There are some things in life that you know are true and it dawns on you. I mentioned The Crack in the Cosmic Egg by Joseph Chilton Pearce. It's when you study a subject so much you suddenly have that intuitive insight. I'm an amateur astronomer — capital A amateur, and I really wanted to be an astronomer before I became a mycologist. I'm just blown away by the cosmos.

    There have been amazing discoveries made on asteroids in the past 10 years. First, a Japanese asteroid retrieval from a probe brought back the basic amino acids that build DNA — A, C, G, T. But another asteroid retrieval is especially interesting. This was called asteroid Bennu. In 2016, NASA sent a probe to Bennu. It took two years to get there, about a year and a half of it circling the asteroid to figure out where to land. They landed the probe, retrieved some asteroid dust, dug into it, and it took about two years for it to come back. In November of 2025, NASA announced not only that they found amino acids — 14 essential amino acids found so far — but they found something else. They found tryptophan. They found tryptophan on Bennu. Tryptophan is very fragile. So the other asteroid retrievals and meteorites coming in, they couldn't find this amino acid. But they found tryptophan — precursor to serotonin.

    Tryptophan decarboxylates, liberates carbon dioxide in one very simple chemical reaction, into tryptamines. Think about it, Andrew. We have tryptamines throughout the universe. We have serotonin likely throughout the universe. These are tryptamine alkaloids. These are happiness molecules. The entire universe is likely filled with tryptamines. And if we have these networks of cells generating tryptamines, it dawned on me that we live in a tryptamine universe. We live in a universal field of consciousness. We'll find mycelium-like organisms throughout the entire universe because that is the way of our neurology. That's the way of mycelium. That's the way of the computer internet. That's the way of dark matter. We may live in this one giant universal consciousness. And we're tiny little apes looking up into the sky wondering what's going on.

    This, I think, unifies all religions. It unifies scientists who are becoming increasingly more spiritual. But we live in a tryptamine universe. To me, this is mind-boggling, and it makes me feel much better about my own mortality. I'll be sad when I die in a sense, but I'm returning to the giant universal consciousness from which we came and of which we are a part right now.

    Andrew Huberman: I'm becoming more and more convinced that our ideas about the brain and biology, while many of them are accurate, are certainly incomplete. So the openness that you have, and these observations which are coming in faster and faster all the time, is exciting. But let's be serious scientists. Where's the proof? Where's the logic in this? Let's stress test this.

    Paul Stamets: And this is what I'm seeing over and over again — these extraordinary imaginative concepts, and we can dare to be wrong. It's important that we dare. It's important that we think creatively, not constrained by tradition, but try to question. I had a sticker on my car for a long time: "Question authority." And I put underneath it: "with respect and humor," because I thought that's the way you create a dialogue. You don't insult somebody. You question them and ask them why they think this way, and both of you can create a dialogue and your imaginations are stimulated and you build a bridge of communication. I just think that we're at this time of great imagination, and this is a time to potentiate the imagination of humans. I think psilocybin and these mushrooms are force multipliers to expand our immunological and neurological health.

    Fungi, the microbiome, and the dangers of antifungals

    Andrew Huberman: I have a question about these electrical fields. You talked about a hypothetical arrangement where we had spikes that would go into the ground and you could transmit those electrical fields into the body. We are of chemicals and electricity — that's not a mystical statement, that's how neurons work and how our cells work. The notion of electricity in the brain hopefully doesn't make people think this is really out there. That's a fundamental concept.

    So that's us getting closer to and more direct interface with these electrical fields. What about the electrical fields and the chemicals from these fungi living in us? Most people nowadays have heard of the microbiome — the microbiota that live in us that can be beneficial or in cases of dysbiosis can be harmful. You talked about elsewhere that the microbiome, or mycobiome — we have fungi living inside of us.

    Paul Stamets: We have a lot of fungi living on our skin. Our skin is one of our biggest organs, and the microbiome of the skin gives us a homeostasis of protection against disease. It's when we use in particular antifungal antibiotics that it can really disrupt the microbiome. I have unfortunately a horrible story of a friend's father who took an antifungal medicine and had an allergic reaction and got thrush — got candida — and he was a big strong man, and apparently his death was so painful, brutal. That's an example of the danger of some of these pharmaceutical antifungals.

    We're more closely related to fungi than any other kingdom. And so we share in common many of the same pathogens. So we use antifungal medicines. This is why it's so hard to get rid of fungal infections — they also tend to be cytotoxic. The microbiome on the skin is something that's being greatly explored. The microbiome internally in the gut is much poorer in our understanding right now. So I can't speak authoritatively on the microbiome internally.

    Eukaryotic fungi and the eukaryotic cells of humans look very, very similar. We're using the bacterial mitochondria as our engine. Typically fungi living in and in between your cells is something that is not good from my limited understanding. So the microbiome on the surface and the microbiome in your gut and homeostasis is really important. The disruption of that is extremely dangerous. So this is airing on the side of caution: just don't screw around with antifungals because the disruption to homeostasis can be extremely bad.

    What I like to admit is when I don't know something, I'll tell you. There are other experts out there — please consult them. They're easily discoverable. The American Dermatological Association has a lot of interesting ideas on the microbiome of fungi that are living on and within the skin cells.

    Mycoremediation — what works and what doesn't

    Andrew Huberman: Two more questions for you if you're willing. The first one is the potential benefits of fungi for cleaning up the planet and maybe even the food supply. The ability of fungi to digest and break down other things is pretty remarkable. Most people nowadays are thinking there's no way to avoid microplastics, there's no way to avoid the particulate that's out in the air. But most people would like to reduce the toxic burden of these things. Is there a way that fungi can be put into the environment in beneficial ways to clean the air, to sequester and maybe break down some of these compounds?

    Paul Stamets: I have literally spent millions, if not tens of millions of dollars on this subject. And I don't want to be a buzzkill, but I can tell you what I've learned. It has been painful and expensive.

    We have very good, reproducible, demonstrable examples that we have published on of mushroom mycelium — like oyster mushrooms — breaking down hydrocarbons: diesel, gasoline, bunker sea oil that ships are burning, from oil spills. Really good. The mycelium takes these polyaromatic hydrocarbons, PAHs, breaks them down at the elemental level, and reassembles them into fungal carbohydrate sugars. I worked with Battelle Laboratories for years. We broke down bunker sea oil from, I think, 20,000 parts per million to 200 parts per million in 16 weeks using oyster mushrooms. Approved for freeway landscaping. It passed the Department of Ecology tests. That really works. So oil spills, mulching — mushroom farms should be reinvented as mycoremediation supply centers, because the waste substrate after the mushrooms form, you can milk it like a cow. It is so full of powerful enzymes that can just break down complex molecules.

    Dioxins — breaking down dioxins, PCBs, polychlorinated biphenyls — from my research has been a disaster. It's very alluring because even though we could break down the dioxins in a petri dish in a laboratory, when we put the mycelium out into the ecosystem, think of it this way: it's like you have a buffet table and you're the fungus and you're hungry and you have all this delicious food on the buffet table and at the end of it this toxin, dioxin. What are you going to eat first? You're going to eat the delicious food. If you starve the mycelium, it will break down the dioxin. So dioxin remediation to me is just not practical.

    Similarly, breaking down plastics. There are some really good examples that have been published for breaking down plastics. Similarly, you throw the mycelium in an ecosystem, it's going to navigate to the foods that are most desirable, and plastics is not something that is high on their list of desirability. So I wish I had good news on dioxins and PCBs and plastics, but some of these recalcitrant polymers that are very tightly bonded — what's the incentive for the mycelium to go after microplastics, which are a small percentage of the food buffet it has in front of it?

    The untapped resource is mushroom farms and their waste substrate. You can compress it, get this beautiful amber product super high in complex enzymes, and then reinflate it by adding water, and the mycelium can produce another flush. I proposed this in my book Mycelium Running — that mushroom farms should be reinvented as mycoremediation centers in every small city.

    The other area that's been very, very successful is microfiltration of E. coli and other contaminants associated with runoff. The mycelium is a filtration membrane. Very good examples have been published in several peer-reviewed journals of mycelial networks capturing E. coli, preventing effluence from farms — chicken farms, cattle ranches — from going into waterways. So the good news is hydrocarbons in general, pesticides, can be broken down. Even things like VX, the nerve gas agents — where there's chemical spills, many of these things are very fragile compounds when the enzymes the mycelium makes contact with them.

    Mycelium does have the ability of sequestering radioactive particles and binding them in a way that is not soluble into water. So it can immobilize some of these toxins. That's a whole different approach — immobilization to prevent it from getting into the food chain.

    So when people approach me on this stuff, I just have to bite my tongue because I spent so much money with great scientists. We have some fantastic successes. But the reality is where I'm going to spend my valuable time. I'm going to spend it on optimization, on longevity, on making people nicer and creating generations of happiness, because the pebbles of the pond of happiness and positivity that we create now will reverberate into the generations of the future.

    Paul Stamets's longevity protocol — push-ups and daily practice

    Andrew Huberman: I certainly second that choice because it's benefiting so many. One last question. Let's talk push-ups. How many push-ups are you doing each day?

    Paul Stamets: I did 95 this morning.

    Andrew Huberman: Maybe share your longevity protocol.

    Paul Stamets: I need to lose some weight, but I haven't been on my bike in the past two weeks. It's a good story because my twin brother — my twin brother's name is North. So of course I was called South. Very competitive, fraternal twins, as different as two twins can be. But we were extremely competitive, and that was a good thing about having a twin brother.

    We started doing these marathon push-ups ever since I was like 10 years of age. I won the push-up contest in Columbiana, Ohio. My record stood for about 10 years. I'm not sure how long, but I was a freshman, in the ninth grade. They opened it up for 9th, 10th, 11th, 12th graders, so lots of guys bigger than me. They had a push-up contest. My twin brother and I said, "Oh, we can do this." We went in, we're ready. And as you probably know, that first 10 to 15 seconds is really important because you spend a lot of energy getting up and getting going. I started doing the push-ups and the coach stopped me after 20 seconds. I'd already done like 30 or 40 push-ups. He said, "No, your nose has to hit the auditorium basketball floor." So he laid down to see if my nose would hit because he thought I was doing them way too fast. And I had to go touch my nose. So I started doing the push-ups and I ended up getting a bloody nose and I pushed up like 40, 50, 67 with blood splattering all over the place. And I won the contest, and the record held for a long time.

    But I point everyone to a Harvard study. Please look this up. It's really extraordinary. Men who can do 40 push-ups — I'm sure it translates to women, a different number of course — if you can do 40 push-ups three times a week, you have a 97% reduction in the potential for cardiac arrest.

    Andrew Huberman: Are all those push-ups done in a single set?

    Paul Stamets: Single set. You have to look it up, but the study — I've looked it up many times, I've referred to it to many people. Fact check me. This is true. Full disclosure, I don't hyperextend my push-ups. I don't go nose to the ground because I don't want to hyperextend my elbows past my body. So I'm about this far off the ground.

    Andrew Huberman: Break 90 degrees at the elbow.

    Paul Stamets: Yeah. Just at my comfort. I know when I hyperextend because my elbows hurt later on. But I just advocate this. This is like, you want actionable solutions — this is probably the most actionable thing that anyone can do, women included: do push-ups. Do a stress test.

    I just came from several conferences on biohacking and I'm learning a lot that I didn't know. I think these chair sit-ups, deep squats, are something I'm going to start incorporating in. But I'm 71 years of age. I have no prescription drugs. I feel like I'm 35. I was born July 17th, 1955. I just can't believe I'm 71 years of age because I look through these eyes and I don't feel it. I don't feel cognitive decline either. But I attribute that to my use of these mushrooms because they're neuro anti-inflammatories in my opinion and of one study. Plus the excitement of the field that you are in breeds creativity. It breeds conversations like this and upregulates my immunity and it's anti-inflammatory by definition. Happiness is the anti-inflammatory drug ultimately. That's what we're seeking.

    Closing reflections — legacy, creativity, and the duty to future generations

    Andrew Huberman: I certainly believe that curiosity driving constructive, productive inquiry and community — Paul, thank you so much for coming here today to discuss your discoveries and your work and the applications. You provide a lot of actionable steps for people to explore and consider, and also just a lot of — I was going to say seeds, should we say spores — for exploration in mental health, in immune system function, cognitive enhancement. And I have to say your enthusiasm around the tryptamine universe concept is one that certainly sparks a lot of interest in me and in many people.

    It's clear to me, if I may, that you are very unusual in your ability to think about very high-level, literally galaxy-and-beyond-wide concepts, but then come right down to the highly reductionist view and go back and forth, traveling back and forth, which is unusual. And I will say it no doubt has fueled the forward progression of this area of science and medicine. You're very humble, and I'm not quite done, so forgive me. Having studied a lot of the history of science and medicine and public health and the way it's progressed, it's always required somebody like you to be able to not just straddle but really travel back and forth in the same conversation from these high-level, at times somewhat abstract concepts, but then get right back to the grounding of things and explain what we need to know in addition to what you are intuiting based on your knowledge and what we already know. So it's a remarkable thing. You mentioned N of one — you are an N of one, and I and many many other people are extremely grateful, and I'm sure that will be true across time for the work that you're doing. Thank you for taking the time to come share your knowledge.

    Paul Stamets: Well, thank you for being a fellow edge runner. I just want to call out to everyone: be creative, because creativity breeds happiness and it breeds community, and then you have the cross-talk of all these receptors that are all in communication and dialogue. This is an opportunity for us to reinvent the human species to optimize, and I think we have all the elements here.

    I would just caution everyone, including myself: be careful about criticizing people until you understand why. Ask the question why. Never take anything that you hear as a fact without asking the question why — with humility, respect, kindness, and engagement. That's how you build these bridges. Our neuroreceptors want to talk to your neuroreceptors. We're all in this together. I think we have an opportunity for a collective genius to come together to find the solutions that we so need.

    I really feel it's so important. First Nations — the concept of seven generations is so true. It's so important. Indigenous peoples have the wisdom that scientists are now proving to be factually true with a different language, but the endpoints are the same. We have a duty to our descendants to do the best that we can. It's not what you make in your lifetime. It's the legacy that you leave. I think all of us can be part of a wonderful legacy if we work together.

    Andrew Huberman: Amen to that. I don't have anything to add. Perfectly stated. Thank you.


    Polished transcript of Andrew Huberman. All views are those of the original speakers. Watch on YouTube ↗
    Published by @healthynut
    More from Andrew Huberman
    More from @healthynut
    Summary